The toxicity of Crysvita can be classified into several categories L2347:
Ectopic mineralisation: Clinically manifested by nephrocalcinosis, has been seen in patients with XLH treated with oral phosphorous and vitamin D analogues. These drugs should be stopped at least 1 week before starting burosumab treatment L2347.
Monitoring for signs and symptoms of nephrocalcinosis, e.g. by renal ultrasonography, is recommended at the beginning of treatment and at intervals of every 6 months for the first 12 months of treatment, and yearly thereafter. Regular monitoring of plasma alkaline phosphatases, Calcium, PTH, and creatinine is advised at 6 months intervals(every 3 months for children 1- 2 years) or as indicated L2347.
Monitoring of urine calcium and phosphate is suggested every 3 months.
Hyperphosphatemia
Fasting serum phosphate level must be followed due to the risk of hyperphosphatemia while taking this drug. To decrease the risk for ectopic mineralization, it is advised that fasting serum phosphate is aimed to be in the lower end of the normal reference range for any given age. Dose interruption and/or dose reduction may be required. Regular measurement of postprandial serum phosphate is advised L2347.
Serum parathyroid hormone increases
Increases in serum parathyroid hormone have been measured in some XLH patients while undergoing treatment with burosumab. Regular measurement of serum parathyroid hormone is recommended L2347.
Injection site reactions
Administration of burosumab, like other injections, can lead to local injection site reactions. Administration of this drug should cease in any patient experiencing severe injection site reactions and appropriate medical therapy administered L2347.
Hypersensitivity
Burosumab should be discontinued if serious hypersensitivity reactions occur and appropriate medical treatment should be provided L2347.
Reproductive toxicity/pregnancy
There are no or limited amount of data available from the use of burosumab in pregnant women. Studies in animals have demonstrated reproductive toxicity. Burosumab use is not advised during pregnancy and in women of childbearing potential/age currently not using contraception L2347.
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets A32593.
The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life L2346.
XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. Most children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain. Some adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss L2346.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Burosumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Burosumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Burosumab. |
| Estrone | Estrone may increase the thrombogenic activities of Burosumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Burosumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Burosumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Burosumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Burosumab. |
| Estriol | Estriol may increase the thrombogenic activities of Burosumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Burosumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Burosumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Burosumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Burosumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Burosumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Burosumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Burosumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Burosumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Burosumab. |
| Equol | Equol may increase the thrombogenic activities of Burosumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Burosumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Burosumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Burosumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Burosumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Burosumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Burosumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Burosumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Burosumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Burosumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Burosumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Burosumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Burosumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Burosumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Burosumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Burosumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Burosumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Burosumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Burosumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Burosumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Burosumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Burosumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Burosumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Burosumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Burosumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Burosumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Burosumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Burosumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Burosumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Burosumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Burosumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Burosumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Burosumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Burosumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Burosumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Burosumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Burosumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Burosumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Burosumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Burosumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Burosumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Burosumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Burosumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Burosumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Burosumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Burosumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Burosumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Burosumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Burosumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Burosumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Burosumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Burosumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Burosumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Burosumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Burosumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Burosumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Burosumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Burosumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Burosumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Burosumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Burosumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Burosumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Burosumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Burosumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Burosumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Burosumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Burosumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Burosumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Burosumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Burosumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Burosumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Burosumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Burosumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Burosumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Burosumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Burosumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Burosumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Burosumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Burosumab. |